Lifelong Premature Ejaculation and How It Differs From the Acquired Kind

• The one licensed treatment whose indication names this presentation specifically
• What guidance actually says about behavioural techniques in the lifelong form, which surprises most people
• Honest success figures from the trials rather than testimonials
• An online consultation with UK registered prescribers, with assessment before anything is supplied

Lifelong premature ejaculation has been present from the earliest experiences rather than developing later. It is also called primary premature ejaculation, and the two terms mean the same thing.

That single distinction changes more than most pages admit. It changes what an assessment can realistically find, it changes which licensed treatment matches the presentation, and it changes what guidance recommends first. On that last point, the guidance says something most online advice for this group gets backwards.

This page sets out the difference between the two forms, what is and is not established about the causes, what the licensed options are, and what the trial figures actually show. Every number here comes from NICE guidance or UK licensed product information.

Key things to know

• Lifelong PE is characterised by ejaculation that has occurred very quickly from the earliest sexual experiences, together with a persistent or recurrent lack of control and associated personal distress. IELT is typically around one minute, although timing alone does not establish the diagnosis.
• Lifelong is characterised by onset from the earliest experiences and persistence through life, with a threshold of less than one to two minutes during intercourse.
• Acquired is characterised by gradual or sudden onset after previous normal experiences.
• NICE states the aetiology of premature ejaculation is unknown, with little data to support suggested biological and psychological factors.
• No genetic cause was identified in any regulator source reviewed for this page.
• Behavioural therapy techniques are not recommended as first line treatment in the lifelong form.

What primary premature ejaculation means

Primary premature ejaculation is the lifelong form, present from the beginning rather than arriving later.

The clinical description

NICE describes lifelong PE as ejaculation occurring very quickly from the earliest sexual experiences. Timing is considered alongside the clinical history and the person's sense of control and distress.

Two elements matter there. The onset is from the start, so there is no period of normal function preceding it. And it persists, rather than appearing and resolving.

The terminology, which is genuinely confusing

Four words describe two things, and people frequently mix them up.

If you have read one term in one place and a different one somewhere else, you may have been reading about the same thing twice. That matters when comparing what different sources say about treatment, because a recommendation for one form is not automatically a recommendation for the other.

Lifelong compared with acquired

The forms differ in onset, in what an assessment is looking for, and in what guidance recommends.

Why the acquired form is easier to investigate

The acquired presentation has a period of previously satisfactory function, so an assessment can explore what changed around the time symptoms began.

That is why an assessment of an acquired presentation asks what happened around the time it started: a new medicine, a change in erectile function, urinary or prostate symptoms, a new diagnosis, a change in circumstances.

What causes primary premature ejaculation

No cause is established. That is the honest position and it comes from the guidance rather than from caution on this page.

What NICE actually says

The aetiology of premature ejaculation is unknown, according to NICE, with little data supporting the biological and psychological hypotheses that have been suggested. Elsewhere the same body notes that although the condition is very common, with prevalence rates of 20 to 30 per cent, its aetiology is poorly understood.

Read the first statement carefully. It is not only that the cause is unknown. It is that the explanations commonly offered, biological and psychological alike, have little data behind them.

Serotonin receptor sensitivity

Serotonergic mechanisms are among the biological hypotheses proposed for lifelong PE.

The licensed tablet is a short acting selective serotonin reuptake inhibitor. NICE describes its mechanism of action in premature ejaculation as presumed to be linked to the inhibition of neuronal reuptake of serotonin, and the subsequent potentiation of that neurotransmitter's action at pre and postsynaptic receptors.

Why that is not proof of a receptor cause

Note the word presumed. Even the medicine's own mechanism is described as presumed rather than demonstrated.

A treatment working through a system does not establish that the system was faulty. The serotonin receptor sensitivity explanation is one of the biological hypotheses NICE describes as having little data supporting it. It is the most discussed of them, and it remains a hypothesis.

The treatment point that surprises people

Guidance says behavioural techniques are not recommended as first line treatment in the lifelong form.

What guidance records

Demonstrated benefit for various behavioural techniques in treating premature ejaculation (PE) is recorded by NICE, which indicates them for men uncomfortable with pharmacological therapy. Their limits get equally candid treatment in the same source: time intensive, dependent on a partner's support, and difficult to do. In the lifelong form specifically, they are not recommended as first line treatment. Behavioural techniques such as stop-start and squeeze techniques may be used as part of management, particularly for men who prefer non-drug approaches or are uncomfortable with pharmacological treatment.

Behavioural therapy may also address performance anxiety and improve communication with a sexual partner, which can influence future intimate relations. While these techniques are less recommended initially for lifelong PE, they remain valuable for managing occasional episodes and improving overall function.

Why this matters for this group

Behavioural approaches are the most commonly shared advice online for premature ejaculation generally, and they are recommended enthusiastically to men with lifelong presentation.

That advice is not worthless, and this page is not telling anyone to abandon an approach that is helping. It is pointing out that for this specific presentation, guidance does not place those techniques first, and somebody who has been persisting with them for months without progress is not failing at something they should be succeeding at.

Where they still have a place

Guidance indicates them for men uncomfortable with medicine based treatment, which is a real and reasonable position to hold.

Among the beneficial non medicine treatments, counselling and education are recorded too. Where anxiety is a substantial part of the picture, addressing that directly is sensible in its own right and does not have to replace anything else. This approach can also help improve overall function and pleasure in intimate relations, especially when performance anxiety or relationship concerns influence future behaviour. It supports better communication with a specific partner and can positively influence future intimate experiences and behaviour.

The licensed options, and which indication names this presentation

A lidocaine and prilocaine cutaneous spray is licensed for the treatment of primary premature ejaculation in adult men.

The cutaneous spray

A lidocaine and prilocaine cutaneous spray is licensed for the treatment of primary premature ejaculation in adult men.

That indication names this presentation specifically. For someone with the lifelong form, the licensed indication and the presentation match exactly, which is not something that can be said for the acquired form.

In its trials, involving 539 patients across two randomised controlled trials, mean measured time rose from a 0.58 minute baseline to 3.17 minutes over three months. The placebo group moved from 0.56 minutes to 0.94 minutes. The product information describes a rapid onset, effective within five minutes of application.

It is particularly useful for those who may have a history of early intimate experiences that affect their current function. The spray works by reducing sensation in the penis, thus delaying the time to reach climax and improving overall satisfaction in intimate relations.

The tablet

A short acting SSRI tablet is licensed for the treatment of premature ejaculation in adult men aged 18 to 64 years. That indication is not restricted by form, so it covers lifelong and acquired presentations alike. The tablet is licensed for premature ejaculation in adult men aged 18 to 64, regardless of whether the presentation is lifelong or acquired. Erectile dysfunction should be assessed separately because it affects treatment decisions.

It is important for men who are sexually active and wish to improve control during intimate activity.

What the tablet brings with it

Very common effects, the band above 1 in 10 men, are dizziness, headache and nausea. Most of the caution is driven by fainting, recorded in 0.06 per cent on the lower strength studied and 0.23 per cent on the higher, against 0.05 per cent on placebo.

It is contraindicated in significant pathological cardiac conditions such as heart failure or significant ischaemic heart disease, in anyone with a history of syncope, and in moderate to severe hepatic impairment. It must not be used alongside phosphodiesterase type 5 inhibitors, the class used for erectile dysfunction, or alongside monoamine oxidase inhibitors, thioridazine, other SSRIs or tricyclic antidepressants.

Combining treatment approaches

This comes up constantly for the lifelong form, and the honest answer has two parts.

Combining a medicine with a non medicine approach

Counselling and education are recorded among the beneficial non medicine treatments, and nothing in guidance frames them as alternatives that exclude a medicine.

Where anxiety has built up over years, which is common in a presentation that has been there since the beginning, addressing it alongside a treatment is reasonable. Counselling or education can be considered alongside pharmacological treatment when clinically appropriate.

Combining the two licensed medicines

No source reviewed for this page establishes the safety or efficacy of using the licensed tablet and the licensed spray together.

That is a verified absence and it should be read as a genuine gap rather than as permission. Anyone considering it should raise it with a prescriber rather than assembling a combination themselves, because nobody has measured what that combination does.

Is lifelong premature ejaculation permanent

No cure is described in the licensed product information or in the guidance reviewed for this page. That is not the same as saying nothing changes.

What the evidence supports

The licensed treatments are used to manage symptoms rather than as treatments that are documented to permanently eliminate lifelong PE. The trials measured what happened while men were taking them, and they did not establish a lasting change after stopping.

NICE also notes limited data on the safety and efficacy of the tablet used as needed beyond 24 weeks, so the long term picture is not well documented either.

The honest framing

Managed rather than cured is the accurate description, and management can be effective.

For a lifelong presentation that framing is arguably easier to accept than for an acquired one, because there is no previous state to return to. The realistic goal is a different pattern from here, not a restoration of something that existed before.

Anyone promising a permanent cure for this form is going beyond what the evidence supports. Results vary between individuals.

What the success figures actually show

Personal accounts of dramatic transformation circulate widely for this condition. The trial figures are more modest and more useful.

Seeing someone about a lifelong presentation

Some men may delay seeking help because they assume that having had PE from the beginning means nothing can be done. That belief is not supported by anything in the guidance.

What an assessment establishes

It confirms whether the pattern meets the diagnostic criteria, checks for the contributors guidance names, and determines which treatments are suitable.

It covers when the pattern began and whether there was ever a period of normal function, whether erectile function has changed, urinary or prostate symptoms, every current medicine including any antidepressant by name, cardiac history including any fainting episode, mental health history including mania or severe depression, liver health, any history of local anaesthetic sensitivity in either person, and alcohol and recreational drug use.

What it will not do

It will not identify the moment things changed, because in a lifelong presentation there was no such moment.

Saying that in advance is more useful than letting somebody leave an assessment feeling it failed. The absence of a discovered cause is the expected outcome here, and it does not prevent treatment.

The two things worth ruling out regardless

Erectile difficulty and genitourinary infection such as prostatitis are named in guidance as things to treat first, and both can coexist with a lifelong pattern.

The erectile question also decides what can be prescribed, since the licensed tablet must not be used alongside erectile dysfunction medicines. The available erectile dysfunction treatments are assessed separately for that reason.

Getting this looked at

An online consultation with UK registered prescribers covers the ground above before anything is supplied. Suitable cases pass to a registered pharmacy for prescribing and dispensing. Unsuitable ones come back with the decision stated plainly and its reasoning attached. The licensed premature ejaculation treatments carry the full detail.

Mention how long the pattern has been present, in plain terms, because the lifelong and acquired distinction changes which indication matches and what an assessment is looking for. Mention anything already tried, including anything bought without a prescription.

The limits of what is set out here

• No cause of lifelong premature ejaculation is established here, because none is established in the guidance. An unknown aetiology is the stated position.
• No genetic cause and no genetic test was identified in any regulator source reviewed.
• No serotonin receptor abnormality is established as a cause. The receptor explanation is a hypothesis described as having little supporting data.
• No cure is described in any source reviewed.
• No safety or efficacy data was identified for using the two licensed treatments together.
• No head to head trial exists between them, so no ranking is supported.
• Dosing is absent from this page by design. Authority on how any medicine is taken rests with the leaflet supplied alongside it.
• No individual outcome is predicted. Results vary between individuals.

Medical Disclaimer

General information rather than medical advice is what this page offers. Both licensed treatments for premature ejaculation are prescription only in the UK and require assessment by a UK registered prescriber. Neither should be used outside its licensed indication, and no data was identified for using them together. Seek medical advice before treatment if you have a cardiac history, any history of fainting, any history of mania or severe depression, liver problems, or if you take antidepressants or erectile dysfunction medicines. Seek medical advice for pain, blood, urinary symptoms, or very low or absent ejaculate volume.